AstraZeneca to cut about 600 US sales jobs, Bloomberg reports
AstraZeneca reportedly cuts about 600 US sales roles in respiratory and immunology units under its savings plan, per Bloomberg News; Reuters has not verified.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
AstraZeneca has reportedly cut about 600 jobs in its respiratory and immunology sales teams in the US as part of its cost-saving program. Bloomberg News reported the move on Friday, citing people familiar with the matter.
Reuters, which carried the report, said it could not immediately verify the information.
why it matters
For investors, this signals that the drugmaker is still pushing its cost-savings program, which could support margins over time. The scale is modest for a company of this size, so the impact on the share price is likely to be limited.
market impact
AstraZeneca: ongoing cost cuts may support margins, but the scale of the reduction is modest
tags
instruments
sources
- Astrazeneca Cuts 600 US Sales Staff As Savings Drive Kicks In- Bloomberg News — Reuters, 13 November 2026 at 16:57 UTC
- AstraZeneca cuts 600 sales jobs in US, Bloomberg News reports — Reuters, 13 November 2026 at 17:05 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗